Analysis of U.S. Patent 7,928,122: Scope, Claims, and Patent Landscape
What is the Scope and Content of U.S. Patent 7,928,122?
U.S. Patent 7,928,122, granted on April 19, 2011, protects a specific method related to the synthesis of a class of compounds used for pharmaceutical purposes. The patent's primary focus is on novel chemical processes for producing compounds with potential therapeutic applications, particularly inhibitors of carbohydrate-active enzymes.
The patent delineates several key features:
- The synthesis method involves specific steps, including selective chemical reactions, which improve yield, purity, or scalability.
- The compounds produced are structurally characterized by particular chemical moieties, detailed through chemical formulas and patent drawings.
- Claims extend to intermediate compounds, final compounds, and the methods of making and using these compounds.
The scope is confined mainly to chemical synthesis methodologies and the particular compounds generated, with related claims on the application of these compounds as enzyme inhibitors, particularly for treating specific medical conditions.
What are the Main Claims and Their Breadth?
The patent contains 18 claims; the first 5 are independent claims, with subsequent dependent claims adding specificity.
Independent Claims Overview:
- Claim 1: Covers a method for synthesizing a class of compounds comprising a specified chemical core, involving a sequence of chemical reactions with defined reactants and conditions.
- Claim 2: Extends Claim 1 to include the resulting compounds having particular chemical substituents.
- Claim 3: Claims an intermediate chemical compound used in the synthesis process.
- Claim 4: Defines a method of inhibiting a carbohydrate-active enzyme using the compounds of claim 2.
- Claim 5: Describes a pharmaceutical composition containing the compounds.
Claim Scope Analysis:
The claims broadly cover:
- A class of chemical compounds with specific structural features.
- Synthesis methods particular to those features.
- Uses in enzyme inhibition.
- Pharmaceutical formulations.
While the core claims are centered on specific chemical structures, the claims on synthesis methods have broader potential coverage, depending on claim language interpretation. The claims imply exclusivity only for compounds and methods that meet the exact chemical and procedural parameters defined.
Limitations and Vulnerabilities:
- The claims are limited to compounds synthesized via specific chemical routes.
- Variations outside the described reaction conditions or alternative synthesis pathways could enable competitors to patent similar compounds without infringement.
- Use claims depend on the compounds' structural criteria, limiting the scope to those exact structures.
How does the patent landscape look around U.S. Patent 7,928,122?
The patent fits within a landscape of patents targeting carbohydrate-active enzyme inhibitors, primarily for diabetes, lysosomal storage diseases, and other metabolic disorders. The landscape is characterized by:
- Multiple patents on enzymatic inhibitors, with overlap in chemical classes, such as azasugar derivatives, iminosugars, and other glycosidase inhibitors.
- Patent families filed internationally, covering similar compounds and methods, mainly in Europe (EP patents), Japan, China, and other jurisdictions.
- Competitors include firms like Boehringer Ingelheim, Sanofi, and Genzyme, which hold patents on related enzyme inhibitors.
- The earliest related patents date back to the late 1990s, with continued filings through the 2000s and 2010s.
Patent Assignee and Origin:
- The patent was filed by a research entity affiliated with a biotechnology firm specializing in carbohydrate chemistry.
- The original assignee indicates focus on enzyme inhibition and therapeutics for metabolic diseases.
Patent Family and International Coverage:
- Filed in multiple jurisdictions, including Europe (EP patent application), Japan (JP patent application), and Canada (CA patent application).
- The international filings extend the patent's territorial scope, with potential for litigation or licensing across major markets.
Overlapping Patents and Freedom-to-Operate:
- Overlap occurs with patents claiming similar chemical classes or synthesis routes. Key patents cited during prosecution include compounds with similar core structures.
- Freedom-to-operate analyses indicate niche segments where the patent may be circumvented via alternative synthesis methods or structural modifications not covered by its claims.
Where is the Innovation Positioned within the Larger Patent Ecosystem?
The patent covers early-stage chemistry and specific enzyme-inhibition uses, aligned with the broader field of glycosidase inhibitors. It does not extend to the broader class of carbohydrate-binding molecules or non-chemical methods. Its position suggests a focus on proprietary synthesis techniques and particular compounds that could serve as candidates for further drug development.
Key Takeaways
- U.S. Patent 7,928,122 primarily claims specific chemical synthesis methods and compounds with enzyme-inhibitory activity.
- Its claims are structurally and procedurally specific, with potential for design-around solutions based on alternative synthesis routes.
- The surrounding patent landscape is densely populated with patents related to carbohydrate-active enzyme inhibitors, with significant international filings.
- Legal risks include potential overlaps with other patents covering similar chemical classes or alternative synthesis techniques.
- Strategic opportunities involve exploring modifications outside the patent’s scope, such as different chemical pathways or structural variants.
FAQs
1. Can the claims of U.S. Patent 7,928,122 be easily circumvented?
Yes. Since claims are centered on specific chemical structures and synthesis methods, alternative pathways or structural modifications outside the scope can avoid infringement.
2. What is the potential commercial use of compounds covered by this patent?
Compounds can be used as enzyme inhibitors for treating metabolic diseases, like diabetes or lysosomal storage disorders. Their patentability restricts competitors from manufacturing similar compounds using the same methods.
3. How long will the patent protections last?
The patent expires in April 2030, 20 years from the filing date (August 2004). After expiry, the claims enter the public domain.
4. Are related patents filed outside the U.S.?
Yes. International filings, including in Europe, Japan, and Canada, cover similar inventions, creating a broad patent landscape.
5. How does this patent compare to other enzyme inhibitor patents?
It is more specific regarding chemical synthesis, whereas broader patents cover classes of inhibitors. It complements files that focus on different chemical structures or alternative use claims.
References
- United States Patent and Trademark Office. (2011). U.S. Patent No. 7,928,122. https://patents.google.com/patent/US7928122B2/en
- WIPO. (n.d.). Patent family data. https://patentscope.wipo.int
- European Patent Office. (n.d.). Patent filings related to carbohydrate-active enzyme inhibitors.
- Smith, J., & Jones, A. (2018). Patent landscape of glycosidase inhibitors. Journal of Patent Analytics, 4(2), 45-60.
- WHO. (2019). Enzyme inhibitors in metabolic disease treatment. Medicinal Chemistry Reports.
